Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Periprocedural myocardial injury (PMI) is common after percutaneous coronary intervention (PCI). Periprocedural infarction (myocardial infarction type 4a) occurs after at least 10% of PCI procedures and has an impact on long-term prognosis. Measurement of biomarkers to allow assessment of PMI is an important tool for clinical and research purposes and should be routine after every PCI (troponin I or T and CK-MB). The importance of oral and intravenous antiplatelet agents and other drugs which have been proven to reduce PMI is discussed.

Original publication

DOI

10.1136/hrt.2009.186189

Type

Journal article

Journal

Heart

Publication Date

05/2010

Volume

96

Pages

736 - 740

Keywords

Angioplasty, Balloon, Coronary, Biomarkers, Cardiotonic Agents, Heart Injuries, Humans, Myocardial Infarction, Platelet Aggregation Inhibitors